Patients younger than 50 years of age at the time of radical prostatectomy appear to have more favorable disease characteristics, data from a European consecutive cohort of non-screened men with clinically localized disease show.
Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer
June 22nd 2023"We're excited that the FDA approval of this radiotracer gives us yet more tools at our disposal to diagnose prostate cancer in all its forms, from early to late in the disease process," says David M. Schuster, MD, FACR.